Timothée Olivier: Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials

Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals, shared a post on X:

“Our new paper out in JAMA Oncology! Co-authored with Alyson Haslam and Vinay Prasad

‘Is it better to treat all patients early on, or to spare those who are already cured and only treat those who relapse?’ Here are some clues, and my coverage of our work.”

Source: Timothée Olivier/X

Timothée Olivier is a medical oncologist at the Oncology Division of Geneva University Hospital in Switzerland. He also serves as a visiting researcher at the University of California, San Francisco. His research focuses on meta-research, evidence-based medicine, health policy, drug regulation, quality of life, medical education, and screening.